1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64D97105365552B92652578FD0031BBF1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/oncology-products-market-entry-initial-trial-thought-leader-engagement-early-education?opendocument
18
19opendocument
2018.212.239.56
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Physician Factors that Shape a Successful Oncology Market Entry: Initial Trial, Thought Leader Engagement, Early Education and New Technologies

ID: 5151


Features:

20 Info Graphics

21 Data Graphics

160+ Metrics

8 Narratives


Pages/Slides: 52


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Physician Factors that Shape a Successful Oncology Market Entry: Initial Trial, Thought Leader Engagement, Early Education and New Technologies"

STUDY OVERVIEW

The pharmaceutical industry is constantly developing and launching new oncology products. While many factors affect a new oncology product launch, physicians play an important role in a product's market entry. Some of the key interactions between pharma and physicians that affect a launch include initial trials, thought leader engagement, early education and use of new technologies.

Best Practices, LLC conducted this study to surface strategies and tactics to address each of these important physician-related areas that are part of a successful oncology product launch. Marketing and launch leaders can use this research to compare their approach to these physician-related launch interactions with the approaches used by leading organizations.

This study includes two segments: one representing the entire benchmark class and one representing the oncology therapeutic area.

KEY TOPICS

  • Winning a physician's initial trial of a new product
  • Thought leader engagement
  • Early physician education
  • New technologies for informing patients and physicians
  • Preparing market constituents

SAMPLE METRICS
  • Effectiveness rating for winning initial trail for new product by physician
  • Effectiveness rating of thought leader engagement strategies
  • Ranking of most important thought leader strategies
  • Effectiveness rating for physician education and engagement strategies
  • Effectiveness rating of new technologies used for educating patients and doctors
  • Importance ranking of stakeholders and winning their support at entering market, winning share and market growth stages of launch

SAMPLE KEY FINDING
  • Medical Affairs Sub-Groups Are Key To Winning KOLS: Identifying the right key opinion leaders to support a scientific platform is critical for successful launches. Just as important is having the right number of KOLs involved. Speaker programs and special studies by specialists are also highly important engagement tools in Oncology. All require the active support and coordinated engagement of Medical Affairs.

METHODOLOGY

The research employed a data gathering approach that gleaned quantitative data from seven leaders in oncology, although their participation varied across the question set. The total benchmark class included 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries. In addition, nine executives participated in in-depth interviews.


Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care; Chemical; Manufacturing; Diagnostic; Consumer Products; Media


Companies Profiled:
GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; AstraZeneca; Genentech; Phillips; TGC MedTech; MedImmune; Abbott; Amgen; Bayer; Actelion; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Bayer Schering Pharma; Quintiles; MerckSerono; Servier; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Urologix; Synapse biomedical; Talecris; NicOx; Eisai; Direct Supply; Shire; ChemGenex Pharmaceuticals; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.